
    
      Fosaprepitant is a prodrug for aprepitant and is rapidly converted to aprepitant after
      intravenous administration; the pharmacological effect of fosaprepitant is attributed to
      aprepitant. The birth to one year old cohort will be initiated in Parts III and IV upon
      completion of Part II (Steps A and B) in participants <6 months of age.
    
  